FY2024 EPS Estimates for Affimed (NASDAQ:AFMD) Raised by Analyst

Affimed (NASDAQ:AFMD - Free Report) - Analysts at Cantor Fitzgerald increased their FY2024 EPS estimates for shares of Affimed in a research note issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will earn ($3.20) per share for the year, up from their prior estimate of ($4.90). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Affimed's current full-year earnings is ($5.92) per share.

A number of other equities research analysts have also recently issued reports on AFMD. StockNews.com assumed coverage on shares of Affimed in a research report on Tuesday, January 2nd. They set a "sell" rating for the company. HC Wainwright increased their target price on shares of Affimed to $10.00 and gave the stock a "buy" rating in a research report on Monday. Finally, Wells Fargo & Company dropped their target price on shares of Affimed from $30.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Affimed has an average rating of "Moderate Buy" and a consensus price target of $45.00.

Affimed Price Performance

Shares of AFMD stock traded down $0.11 during mid-day trading on Thursday, reaching $6.55. The company's stock had a trading volume of 143,344 shares, compared to its average volume of 101,021. Affimed has a 1-year low of $2.23 and a 1-year high of $11.10. The company has a market cap of $99.76 million, a P/E ratio of -0.78 and a beta of 2.05. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.67 and a current ratio of 3.70. The firm's 50-day moving average is $5.49 and its two-hundred day moving average is $4.93.

Institutional Investors Weigh In On Affimed

Hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Affimed in the 1st quarter valued at about $27,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Affimed in the 2nd quarter valued at about $31,000. UBS Group AG boosted its stake in shares of Affimed by 42.2% in the 1st quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 13,979 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Affimed by 30.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 3,202 shares during the last quarter. Finally, Advisor Group Holdings Inc. boosted its stake in shares of Affimed by 258.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company's stock valued at $40,000 after purchasing an additional 6,464 shares during the last quarter. Institutional investors own 30.82% of the company's stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.